Fog is a huge problem for drivers out there, but technology giant Microsoft has come up with a new-generation idea that could help deal with it once and for all.
Many years ago, the great philosopher Plutarch raised the following scenario:
The ship wherein Theseus and the youth of Athens returned from Crete had thirty oars, and was preserved by the Athenians down even to the time of Demetrius Phalereus, for they took away the old planks as they decayed, putting in new and stronger timber in their places, insomuch that this ship became a standing example among the philosophers, for the logical question of things that grow; one side holding that the ship remained the same, and the other contending that it was not the same. (Plutarch, Theseus, 75AD)
To print this article, all you need is to be registered or login on Mondaq.com.
A patent term extension (PTE) provides a valuable mechanism for an Australian patent holder to extend the term of a pharmaceutical patent beyond the standard 20-year term. The PTE provisions are designed to compensate a patentee for the relatively long time required to develop, test and obtain regulatory approval to commercialise a new drug.
PTE Requirements
An application for a PTE can be made when (i) the patent relates to a pharmaceutical substance or a pharmaceutical substance when produced by recombinant DNA technology, (ii) the substance is included on the Australian Register of Therapeutic Goods (ARTG) before the 20-year term of the patent expires, and (iii) at least five years have elapsed between the effective filing date of the patent application and the first inclusion of the pharmaceutical on the ARTG.
On January 14, 2021, the Federal Court issued a decision
(
Janssen Inc. et al v. Apotex Inc. et al, 2021 FC 7) in
the consolidated infringement action brought under s. 6(1) of the
Patented Medicine (Notice of Compliance) (PM(NOC))
Regulations by Janssen against Apotex, Dr. Reddy s
Laboratory, and Pharmascience. In this decision, the Court
invalidated the asserted claims of Janssen s Canadian Patent
2,661,422 (the 422 Patent), which claimed the combined use of the
two active ingredients found in Janssen s brand name drug
ZYTIGA, abiraterone acetate and prednisone, in the treatment of
prostate cancer. Concurrently, the Court dealt with Apotex
counterclaim under s. 6(3) of the
PM(NOC) Regulations to
SCOTTS VALLEY (dpa-AFX) - Nidec Corp. (NJ) said that it filed a patent infringement lawsuit against Seagate Technology LLC and its affiliates on January 18 in the United States District Court